[go: up one dir, main page]

SI3558997T1 - Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka - Google Patents

Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka

Info

Publication number
SI3558997T1
SI3558997T1 SI201730707T SI201730707T SI3558997T1 SI 3558997 T1 SI3558997 T1 SI 3558997T1 SI 201730707 T SI201730707 T SI 201730707T SI 201730707 T SI201730707 T SI 201730707T SI 3558997 T1 SI3558997 T1 SI 3558997T1
Authority
SI
Slovenia
Prior art keywords
amino
treating cancer
triazolopyridine compounds
triazolopyridine
compounds
Prior art date
Application number
SI201730707T
Other languages
English (en)
Inventor
Maurice Raymond Verschoyle Finlay
Frederick Woolf Goldberg
Attilla Kuan Tsuei Ting
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI3558997T1 publication Critical patent/SI3558997T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201730707T 2016-12-20 2017-12-19 Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka SI3558997T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436619P 2016-12-20 2016-12-20
PCT/EP2017/083625 WO2018114999A1 (en) 2016-12-20 2017-12-19 Amino-triazolopyridine compounds and their use in treating cancer
EP17825829.9A EP3558997B1 (en) 2016-12-20 2017-12-19 Amino-triazolopyridine compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
SI3558997T1 true SI3558997T1 (sl) 2021-07-30

Family

ID=60937727

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730707T SI3558997T1 (sl) 2016-12-20 2017-12-19 Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka

Country Status (39)

Country Link
US (4) US10407446B2 (sl)
EP (1) EP3558997B1 (sl)
JP (1) JP6883653B2 (sl)
KR (1) KR102220971B1 (sl)
CN (1) CN110177791B (sl)
AR (1) AR110400A1 (sl)
AU (1) AU2017384388B2 (sl)
BR (1) BR112019012217B1 (sl)
CA (1) CA3046339C (sl)
CL (1) CL2019001714A1 (sl)
CO (1) CO2019007810A2 (sl)
CR (1) CR20190301A (sl)
CY (1) CY1124239T1 (sl)
DK (1) DK3558997T3 (sl)
DO (1) DOP2019000168A (sl)
EA (1) EA037745B1 (sl)
EC (1) ECSP19044159A (sl)
ES (1) ES2867274T3 (sl)
HR (1) HRP20210548T1 (sl)
HU (1) HUE054548T2 (sl)
IL (1) IL267158B (sl)
JO (1) JOP20190151B1 (sl)
LT (1) LT3558997T (sl)
MA (1) MA47079B1 (sl)
MX (1) MX390535B (sl)
MY (1) MY183036A (sl)
NI (1) NI201900062A (sl)
NZ (1) NZ755222A (sl)
PE (1) PE20191474A1 (sl)
PH (1) PH12019501350B1 (sl)
PL (1) PL3558997T3 (sl)
PT (1) PT3558997T (sl)
RS (1) RS61701B1 (sl)
SI (1) SI3558997T1 (sl)
SM (1) SMT202100225T1 (sl)
TW (1) TWI776835B (sl)
UA (1) UA123032C2 (sl)
WO (1) WO2018114999A1 (sl)
ZA (1) ZA201904695B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054548T2 (hu) 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2020186211A1 (en) * 2019-03-13 2020-09-17 The Uab Research Foundation Methods and compositions for treating polyoma virus infection
JP7696834B2 (ja) * 2019-05-27 2025-06-23 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド Ｄｎａ依存性タンパク質キナーゼ阻害剤
WO2020257325A1 (en) 2019-06-17 2020-12-24 Vertex Pharmaceuticals Inc. Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CN114728978A (zh) * 2019-11-22 2022-07-08 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并吡咯类螺环化合物及其衍生物
JP7383818B2 (ja) * 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物
KR20220150879A (ko) * 2019-11-26 2022-11-11 프리뮨 테라퓨틱스, 인크. Tlr7 효능제
CN113121573A (zh) * 2019-12-31 2021-07-16 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
KR102786205B1 (ko) * 2019-12-31 2025-03-31 청두 바이위 파머수티컬 씨오., 엘티디 퓨린 유도체 및 의학에서의 그의 용도
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂
NZ793536A (en) * 2020-04-17 2025-11-28 Kangbaida Sichuan Biotechnology Co Ltd Imidazolidinone derivatives and medical use thereof
WO2021213460A1 (zh) * 2020-04-23 2021-10-28 山东轩竹医药科技有限公司 三并环类激酶抑制剂
JP2023524666A (ja) 2020-04-28 2023-06-13 インテリア セラピューティクス，インコーポレイテッド インビトロ細胞送達の方法
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
CN116406272A (zh) * 2020-07-20 2023-07-07 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
US12280049B2 (en) * 2020-08-04 2025-04-22 Astrazeneca Ab Methods of delaying pain progression and treating prostate cancer
CN114249753A (zh) * 2020-09-22 2022-03-29 山东轩竹医药科技有限公司 三唑并吡啶类激酶抑制剂
JP2023542548A (ja) * 2020-09-24 2023-10-10 オークランド ユニサービシズ リミテッド 新規アミノピリジン及びその癌治療への使用
CN114573605A (zh) * 2020-12-01 2022-06-03 武汉光谷亚太医药研究院有限公司 Dna依赖蛋白激酶抑制剂及其应用
CN114634522A (zh) * 2020-12-15 2022-06-17 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
EP4263829A1 (en) 2020-12-17 2023-10-25 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
WO2022135555A1 (zh) * 2020-12-24 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
TW202309034A (zh) 2021-04-17 2023-03-01 美商英特利亞醫療公司 Dna依賴性蛋白質激酶抑制劑以及其組合物及用途
JP2024521565A (ja) * 2021-05-19 2024-06-03 ザイ ラボ （シャンハイ） カンパニー、リミテッド． 複素環置換のプリノン誘導体の塩の形及び結晶
WO2023274310A1 (zh) * 2021-06-29 2023-01-05 成都百裕制药股份有限公司 嘌呤衍生物的晶型及其药物组合物
CN116023394B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023393B (zh) * 2021-10-25 2025-08-12 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
CN116023395B (zh) * 2021-10-25 2025-07-15 山东轩竹医药科技有限公司 三环类激酶抑制剂的晶型
US20250305004A1 (en) * 2022-05-13 2025-10-02 The Board Of Trustees Of The Leland Stanford Junior University Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment
IL321260A (en) 2022-12-06 2025-08-01 Astrazeneca Ab Polq inhibitors
WO2025023957A1 (en) * 2023-07-21 2025-01-30 Wei Zhong Substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8h-purin-8-one compounds and their use in treating cancer
WO2025049481A1 (en) 2023-08-28 2025-03-06 Intellia Therapeutics, Inc. Methods of editing an hla-a gene in vitro
WO2025181336A1 (en) 2024-03-01 2025-09-04 Cellectis Sa Compositions and methods for hbb-editing in hspc
WO2025248119A1 (en) 2024-05-31 2025-12-04 Astrazeneca Ab 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors
WO2025248117A1 (en) 2024-05-31 2025-12-04 Astrazeneca Ab 6-aminopurine derivatives useful as polq inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2005080334A1 (ja) 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 新規へテロ環化合物
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007035873A1 (en) 2005-09-21 2007-03-29 Pharmacopeia, Inc. Purinone derivatives for treating neurodegenerative diseases
US20080004295A1 (en) 2005-10-13 2008-01-03 Gore Paul M Novel compounds
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
EP2457913B1 (en) 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
MX2009013728A (es) 2007-06-15 2010-01-25 Banyu Pharma Co Ltd Derivados de bicicloanilina.
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2009122180A1 (en) 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
UA110697C2 (uk) 2010-02-03 2016-02-10 Сігнал Фармасьютікалз, Елелсі ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
SG194216A1 (en) 2011-04-21 2013-11-29 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
AR086196A1 (es) 2011-04-21 2013-11-27 Origenis Gmbh Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6121658B2 (ja) 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
SG10201912850WA (en) 2011-10-19 2020-02-27 Signal Pharm Llc Treatment Of Cancer With TOR Kinase Inhibitors
KR20200034818A (ko) * 2012-03-15 2020-03-31 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
CN102675897B (zh) 2012-05-18 2015-04-29 陕西师范大学 硫脲/脲芳胺染料及其制备方法和应用
CN103864792B (zh) 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
EP2961408A1 (en) 2013-02-28 2016-01-06 Signal Pharmaceuticals, LLC Treatment of cancer with tor kinase inhibitors
NO2714752T3 (sl) 2014-05-08 2018-04-21
HUE054548T2 (hu) 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében

Also Published As

Publication number Publication date
SMT202100225T1 (it) 2021-05-07
KR20190092573A (ko) 2019-08-07
AU2017384388B2 (en) 2020-09-17
TW201837045A (zh) 2018-10-16
DOP2019000168A (es) 2019-07-15
JP2020504107A (ja) 2020-02-06
CN110177791A (zh) 2019-08-27
US11136340B2 (en) 2021-10-05
ES2867274T3 (es) 2021-10-20
JOP20190151B1 (ar) 2023-09-17
MY183036A (en) 2021-02-08
IL267158A (en) 2019-08-29
US20220041625A1 (en) 2022-02-10
PT3558997T (pt) 2021-04-13
TWI776835B (zh) 2022-09-11
MA47079A (fr) 2019-10-30
BR112019012217B1 (pt) 2021-08-10
HUE054548T2 (hu) 2021-09-28
CL2019001714A1 (es) 2019-09-06
ZA201904695B (en) 2021-05-26
ECSP19044159A (es) 2019-06-30
EP3558997A1 (en) 2019-10-30
CN110177791B (zh) 2022-07-12
EP3558997B1 (en) 2021-01-27
AU2017384388A1 (en) 2019-07-25
MA47079B1 (fr) 2021-05-31
IL267158B (en) 2020-10-29
LT3558997T (lt) 2021-04-26
JOP20190151A1 (ar) 2019-06-20
KR102220971B1 (ko) 2021-02-25
NZ755222A (en) 2022-07-01
PH12019501350A1 (en) 2020-01-20
US11746118B2 (en) 2023-09-05
HRP20210548T1 (hr) 2021-05-14
PH12019501350B1 (en) 2024-02-23
AR110400A1 (es) 2019-03-27
US20180194782A1 (en) 2018-07-12
UA123032C2 (uk) 2021-02-03
CO2019007810A2 (es) 2019-10-09
PL3558997T3 (pl) 2021-07-19
BR112019012217A2 (pt) 2019-11-12
EA201991399A1 (ru) 2020-01-22
CA3046339C (en) 2022-02-22
JP6883653B2 (ja) 2021-06-09
PE20191474A1 (es) 2019-10-16
CA3046339A1 (en) 2018-06-28
EA037745B1 (ru) 2021-05-18
NI201900062A (es) 2020-07-22
RS61701B1 (sr) 2021-05-31
MX2019007189A (es) 2019-10-09
MX390535B (es) 2025-03-20
US10407446B2 (en) 2019-09-10
CR20190301A (es) 2019-09-04
US20240124492A1 (en) 2024-04-18
DK3558997T3 (da) 2021-04-19
US20200048281A1 (en) 2020-02-13
WO2018114999A1 (en) 2018-06-28
CY1124239T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
IL276733A (en) Use of Aribolin in cancer treatment
IL249020A0 (en) 1,3,4-thiadiazole compounds and their use in cancer treatment
GB201511382D0 (en) Novel compounds and their use in therapy
SG11202104571RA (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1, 3, 4-thiadiazole compounds and their use for cancer treatment
IL251903B (en) Epilimod for use in the treatment of colon cancer
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
IL258644A (en) 4,3,1-thiadiazole compounds and their use for cancer treatment
ZA201802618B (en) Anti-cd43 antibody and use thereof for cancer treatment
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL262143A (en) Improvements in cancer treatment
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
GB201514015D0 (en) Novel pyridazinones and their use in the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
IL255541A (en) Cabazitaxel and its use for treating cancer
GB201609402D0 (en) Materials and methods for treating cancer
GB201514018D0 (en) Novel tricyclic compounds and their use in the treatment of cancer
ZA201904626B (en) Cancer treatment method and composition
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB2578008B (en) 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment
HK1259160A1 (en) Bis-pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer